May 15, 2002

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Aza C treatment results in significantly higher response rates, improved quality of life, reduced risk of leukemic transformation, and improved survival compared with supportive care. Aza C provides a new treatment option that is superior to supportive care for patients with the MDS subtypes and specific entry criteria treated in this study.

Me gusta

Guardar

Cite This Study

Silverman et al. (Wed,) studied this question.

synapsesocial.com/papers/69ecef1dd55980bedc8fe5c0 https://doi.org/https://doi.org/10.1200/jco.2002.04.117

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Nonparametric Estimation from Incomplete Observations1958 · 39,019 citations
2Responses of hemopoietic precursors to 13-cis retinoic acid and 1,25 dihydroxyvitamin D3 in the myelodysplastic syndromes1986 · 45 citations
3Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases1998 · 1,786 citations
4Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome.1999 · 8 citations
5Erythropoietin treatment in patients with myelodysplastic syndrome and anemia.1991 · 46 citations

Me gusta

Guardar